The U.S. Food and Drug Administration (FDA) recently approved of a priority review of the biologics license application (BLA) for olaratumab, a medicine designed to treat advanced soft tissue sarcoma (STS).

The Committee for Medicine Products for Human Use (CHMP) branch of the European Medicines Agency recently granted a positive opinion to broaden the indication of Amgen’s Kyprolis (carfilzomib) treatment for relapsed multiple myeloma.

Shire plc recently announced that the Committee for Medicine Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion of Revestive (teduglutide) to treat pediatric short bowl syndrome patients.

AstraZeneca recently announced that it has finished its U.S. licensing agreement for the exclusive U.S. rights to Zurampic, also called lesinurad, as well as the fixed-dose lesinurad and allopurinol combination from Ironwood Pharmaceuticals.

Purdue Pharma LP recently announced that it has entered into a patent agreement with Acura Pharmaceuticals Inc. and Egalet Corporation to settle a variety of patent claims.

BioMarin Pharmaceutical Inc. recently announced its decision to withdraw its Marketing Authorization Application (MAA) for Kyndrisa (drisapersen) from Europe after holding the May 2016 Committee for Medicines Agency (EMA) meeting.

AbbVie, a worldwide biopharmaceutical company, recently announced that officials at the European Commission (EC) have approved Imbruvica to be used as a first-line treatment option for chronic lymphocytic leukemia (CLL).

The Committee for Medicine Products for Human Use (CHMP) branch of the European Medicines Agencies (EMA) recently granted a positive opinion of Zepatier, a Merck product.

Leaders at the U.S. Food and Drug Administration (FDA) recently granted approval of Probuphine, which is the first buprenorphine implant that is designed to treat opioid dependence.

Leaders at the American Medical Association (AMA) recently congratulated the U.S. Food and Drug Administration (FDA) for modifying its Nutrition Facts Label to emphasize the sugar levels in food products.

The American Heart Association recently applauded the draft legislation from the Senate that could end the 'all-or-nothing approach' and implement meaningful use of the Medicare and Medicaid Electronic Health Records Incentive Programs.

The Agency for Healthcare Research and Quality (AHRQ) has developed a program, called the Health Care Safety Hotline project, to improve the quality and safety of medical events for patients throughout the U.S.

The American Heart Association (AHA) recently opened its guidelines-compliant BLS and ACLS courses, which are designed to help attendees better recognize and implement the emergency response system in an emergency situation.

MedImmune, the worldwide biologics research and development branch of AstraZeneca, recently gained Fast Track designation for its MEDI18852, an investigational human monoclonal antibody (mAb), from the U.S. Food and Drug Administration (FDA).

The American Medical Association (AMA) recently released a statement that celebrates the new rule from the U.S. Food and Drug Administration (FDA) about e-cigarettes and other tobacco products.

The U.S. Food and Drug Administration (FDA) recently finalized a new rule that effectively enforces its authority for regulating all tobacco products, including cigars, e-cigarettes, pipe and hookah tobacco.

Leaders at the American Heart Association (AHA) recently stated that giving authority to the U.S. Food and Drug Administration (FDA) to guide menu labeling will give consumers more information about their food.

The U.S. Food and Drug Administration (FDA) recently granted approval to a brand name change for Brintellix (vortioxetine), an antidepressant drug, which sounds similar to Brilinta (ticagrelor), an antiplatelet drug.

Leaders at the U.S. Food and Drug Administration (FDA) recently published their final implementation date for restaurants to label menus, allowing consumers to improve their food choices to decrease the risk of developing cancer.

The U.S. Food and Drug Administration (FDA) recently granted approval for Nuplazid (pimavanserin) tablets, which are the first treatment for the hallucinations and delusions that accompany the psychosis that some Parkinson’s patients experience.